A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

Published:2011-11-23 Issue:3 Volume:156 Page:326-333
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Khan Meaghan L.,Reeder Craig B.,Kumar Shaji K.,Lacy Marthy Q.,Reece Donna E.,Dispenzieri Angela,Gertz Morie A.,Greipp Phillip,Hayman Suzanne,Zeldenhurst Steven,Dingli David,Lust John,Russell Stephen,Laumann Kristina M.,Mikhael Joseph R.,Leif Bergsagel P.,Fonseca Rafael,Vincent Rajkumar S.,Keith Stewart A.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08949.x/fullpdf

Reference25 articles.

1. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma;Barlogie;British Journal of Haematology,2006

2. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy;Blansfield;Clinical Cancer Research,2008

3. Recent major improvement in long-term survival of younger patients with multiple myeloma;Brenner;Blood,2008

4. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients;Gay;Blood,2010

5. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy;Hideshima;Blood,2000

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients;Annals of Saudi Medicine;2024-03

2. Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma;Cancer Medicine;2022-11-15

3. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation;Transplantation and Cellular Therapy;2022-06

4. Multiple myeloma: Unveiling the survival data with different lines of treatments;Journal of Cancer Research and Therapeutics;2022

5. The Evaluation of Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients;Turkish Journal of Hematology;2021-05-04